After temporary reprieve, Advanz Pharma's liver med Ocaliva loses marketing nod in Europe

After a rough few months for Intercept and Advanz Pharma's Ocaliva on both sides of the Atlantic, the other shoe has dropped for the rare liver disease drug in Europe.